Logo

Todd Druley, Sandra Close, Karen Fritschen,

Mar 06, 2019

ArcherDx has appointed Todd Druley as the firm's chief medical officer, Sandra Close as the senior VP of regulatory and diagnostic strategy, and Karen Fritschen as VP of human resources.

Prior to joining ArcherDx, Druley most recently served as an associate professor of pediatrics, hematology, and oncology at Washington University of Medicine in St. Louis. He is an inductee into the American Society of Clinical Investigators and serves as a scientific advisor for Alex's Lemonade Stand Foundation, the Gateway Chapter of the Leukemia & Lymphoma Society, the Kids Shouldn't Have Cancer Foundation, the B+ Foundation, and the Eli Seth Matthews Leukemia Foundation. Druley will continue to see children with cancer predisposition as well as oversee his academic research lab at WUSTL.

Before joining ArcherDx, Close served as CEO of GenEngine. In addition she was responsible for building the health outcomes function for Baxter Healthcare/Caremark. She also lead the research and biomarker functions, including personalized medicine and companion diagnositics at Eli Lilly. Close also previously served as Arrogen's chief scientific officer.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.